Zobrazeno 1 - 10
of 16
pro vyhledávání: '"D. S. Dougherty"'
Autor:
Elizabeth Fisher, Richard A. Rudick, D. S. Dougherty, Monika Baier, Michele Mass, N. A. Simonian, Jar-Chi Lee, Jack H. Simon, Bianca Weinstock-Guttman, Gary Cutter, David Miller
Publikováno v:
Neurology. 59:1412-1420
Objective: To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86937630e0c6555e4d864e22f96bcbcb
https://doi.org/10.1212/01.wnl.0000036271.49066.06
https://doi.org/10.1212/01.wnl.0000036271.49066.06
Autor:
R. H. Whitham, D. S. Dougherty, P. M. Pullicino, David M. Bartoszak, Michael E. Coats, J. S. Fischer, Jack H. Simon, C. M. Brownscheidle, L. D. Jacobs, Richard A. Rudick, B. Weistock-Guttman, N. A. Simonian, B. J. Scherokman, J. R. Richert, C. V. Granger, Robert M. Herndon, Michele Mass, D. L. Cookfair, Andres M. Salazar, R. L. Priore, J. J. Alam, R. P. Kinkel, Dennis Bourdette, F. E. Munschauer, Jonathan Braiman, S. L. Cohan, Donald E. Goodkin, M. K. Campion
Publikováno v:
Neurology. 49:358-363
Background and Objective: A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-la (IFNβ-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e29bb515d0eef4fe10f80d9ae4105c35
https://doi.org/10.1212/wnl.49.2.358
https://doi.org/10.1212/wnl.49.2.358
Autor:
R A, Rudick, D E, Goodkin, L D, Jacobs, D L, Cookfair, R M, Herndon, J R, Richert, A M, Salazar, J S, Fischer, C V, Granger, J H, Simon, J J, Alam, N A, Simonian, M K, Campion, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R L, Priore, P M, Pullicino, B J, Scherokman, B, Weistock-Guttman, R H, Whitham
Publikováno v:
Neurology. 57(12 Suppl 5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d81f0874df8696917c43e6fb38fbf53a
https://pubmed.ncbi.nlm.nih.gov/11902591
https://pubmed.ncbi.nlm.nih.gov/11902591
Autor:
N. A. Simonian, Richard A. Rudick, D S Dougherty, Monika Baier, Michele Mass, Deborah M. Miller, Gary Cutter, Elizabeth Fisher, Bianca Weinstock-Guttman
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 6(6)
Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e90e16a1d17c649f2329c2d7b5f41ed
https://pubmed.ncbi.nlm.nih.gov/11212131
https://pubmed.ncbi.nlm.nih.gov/11212131
Autor:
R A, Rudick, D L, Cookfair, N A, Simonian, R M, Ransohoff, J R, Richert, L D, Jacobs, R M, Herndon, A M, Salazar, J S, Fischer, C V, Granger, D E, Goodkin, J H, Simon, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munchsauer, K, O'Reilly, R L, Priore, R H, Whitham
Publikováno v:
Journal of neuroimmunology. 93(1-2)
This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III clinical trial of IFNbeta-Studies supported by the National Multiple Sclerosis Society (gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13f8a411328cfa8b2d962e4b41cd40a6
https://pubmed.ncbi.nlm.nih.gov/10378864
https://pubmed.ncbi.nlm.nih.gov/10378864
Autor:
D E, Goodkin, R L, Priore, K E, Wende, M, Campion, D N, Bourdette, R M, Herndon, J S, Fischer, L D, Jacobs, D L, Cookfair, R A, Rudick, J R, Richert, A M, Salazar, C V, Granger, J H, Simon, J J, Alam, D M, Bartoszak, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R H, Whitham
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 4(6)
We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25 feet (TA) and manual dexterity (the Box and Block Test [BBT], and 9-Hole Peg Test [9HPT]) to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4cbec0bcb408388be21c121001352b2e
https://pubmed.ncbi.nlm.nih.gov/9987756
https://pubmed.ncbi.nlm.nih.gov/9987756
Autor:
R A, Rudick, D E, Goodkin, L D, Jacobs, D L, Cookfair, R M, Herndon, J R, Richert, A M, Salazar, J S, Fischer, C V, Granger, J H, Simon, J J, Alam, N A, Simonian, M K, Campion, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R L, Priore, R H, Whitham
Publikováno v:
Neurology. 49(2)
A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outcome was time from study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c7783e2a2501640a2e27e5006f5d19ba
https://pubmed.ncbi.nlm.nih.gov/9270562
https://pubmed.ncbi.nlm.nih.gov/9270562
Autor:
L D, Jacobs, D L, Cookfair, R A, Rudick, R M, Herndon, J R, Richert, A M, Salazar, J S, Fischer, D E, Goodkin, C V, Granger, J H, Simon, J J, Alam, D M, Bartoszak, D N, Bourdette, J, Braiman, C M, Brownscheidle, M E, Coats, S L, Cohan, D S, Dougherty, R P, Kinkel, M K, Mass, F E, Munschauer, R L, Priore, P M, Pullicino, B J, Scherokman, R H, Whitham
Publikováno v:
Annals of neurology. 39(3)
The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f379bfe0a277fa6e5b29536620ab80b5
https://pubmed.ncbi.nlm.nih.gov/9403493
https://pubmed.ncbi.nlm.nih.gov/9403493
Autor:
D. S. Dougherty
Publikováno v:
Annals of Otology, Rhinology & Laryngology. 20:434-440
n/a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4a2fd8cef99937dd38063e09bc8c6c1
https://doi.org/10.1177/000348941102000212
https://doi.org/10.1177/000348941102000212
Autor:
D S, Dougherty
Publikováno v:
Atlanta journal-record of medicine. 7(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a733c371a76e9831c62c351b69533bff
https://pubmed.ncbi.nlm.nih.gov/36019676
https://pubmed.ncbi.nlm.nih.gov/36019676